Middle East respiratory syndrome coronavirus infection medical therapy: Difference between revisions
Joao Silva (talk | contribs) |
Joao Silva (talk | contribs) |
||
| Line 8: | Line 8: | ||
==Medical Therapy== | ==Medical Therapy== | ||
[[MERS]] represents a great challenge in terms of treatment because it is caused by a relatively novel [[virus]] to which there is no approved therapy yet. According to | [[MERS]] represents a great challenge in terms of treatment because it is caused by a relatively novel [[virus]] to which there is no approved therapy yet. According to | ||
the ''International Severe Acute Respiratory & Emerging Infection Consortium'' (ISARIC), supportive medical care continues to be the approved treatment for [[MERS]]. Recent studies are showing the potential use of other [[drugs]] and therapies to treat the [[MERS-CoV]], which are based on the experience in treating other [[coronaviruses]] like the [[SARS virus]]. This repurposing of [[drugs]] has advantages such as: better availability, lower cost and known safety and tolerability profiles. However, lack of evidence makes these new therapies uncertain.<ref name="pmid24841273">{{cite journal| author=Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J et al.| title=Repurposing of clinically developed drugs for treatment of Middle East Respiratory Coronavirus Infection. | journal=Antimicrob Agents Chemother | year= 2014 | volume= | issue= | pages= | pmid=24841273 | doi=10.1128/AAC.03036-14 | pmc= | url=http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139281416 }} </ref> ISARIC recommends, additionally to routine investigations, that some approaches are more worth of consideration for experiment. These include:<ref name=ISARIC>{{cite web | title = Treatment of MERS-CoV: Decision Support Tool | url = http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139281416 }}</ref> | the ''International Severe Acute Respiratory & Emerging Infection Consortium'' (ISARIC), supportive medical care continues to be the approved treatment for [[MERS]]. The search for broad-spectrum inhibitors aiming to minimize the impact of [[coronaviruses]] [[infections]] remains the major goal. Recent studies are showing the potential use of other [[drugs]] and therapies to treat the [[MERS-CoV]], which are based on the experience in treating other [[coronaviruses]] like the [[SARS virus]]. This repurposing of [[drugs]] has advantages such as: better availability, lower cost and known safety and tolerability profiles. However, lack of evidence makes these new therapies uncertain.<ref name="pmid24841273">{{cite journal| author=Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J et al.| title=Repurposing of clinically developed drugs for treatment of Middle East Respiratory Coronavirus Infection. | journal=Antimicrob Agents Chemother | year= 2014 | volume= | issue= | pages= | pmid=24841273 | doi=10.1128/AAC.03036-14 | pmc= | url=http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139281416 }} </ref> ISARIC recommends, additionally to routine investigations, that some approaches are more worth of consideration for experiment. These include:<ref name=ISARIC>{{cite web | title = Treatment of MERS-CoV: Decision Support Tool | url = http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139281416 }}</ref> | ||
*'''Convalescent [[plasma]]''' - this therapy, along with others that involve [[antibodies]] for the [[MERS-CoV]] has the strongest evidence for intervention. [[Plasma]] from patients who recovered from [[MERS-CoV]] [[infection]] contains neutralizing [[antibodies]], which represents the best therapy to neutralize the [[extracellular]] [[virus]]. | *'''Convalescent [[plasma]]''' - this therapy, along with others that involve [[antibodies]] for the [[MERS-CoV]] has the strongest evidence for intervention. [[Plasma]] from patients who recovered from [[MERS-CoV]] [[infection]] contains neutralizing [[antibodies]], which represents the best therapy to neutralize the [[extracellular]] [[virus]]. | ||
*'''[[Intravenous immunoglobulin]]''' - | *'''[[Intravenous immunoglobulin]]''' - | ||
Revision as of 20:13, 17 June 2014
|
Middle East Respiratory Syndrome Coronavirus Infection Microchapters |
|
Differentiating Middle East Respiratory Syndrome Coronavirus Infection from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Middle East respiratory syndrome coronavirus infection medical therapy On the Web |
|
American Roentgen Ray Society Images of Middle East respiratory syndrome coronavirus infection medical therapy |
|
FDA on Middle East respiratory syndrome coronavirus infection medical therapy |
|
CDC on Middle East respiratory syndrome coronavirus infection medical therapy |
|
Middle East respiratory syndrome coronavirus infection medical therapy in the news |
|
Blogs on Middle East respiratory syndrome coronavirus infection medical therapy |
|
Directions to Hospitals Treating Middle East respiratory syndrome coronavirus infection |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Middle East Respiratory Syndrome (MERS) is a viral respiratory illness. It is caused by an emerging coronavirus, specifically a betacoronavirus called MERS-CoV (Middle East Respiratory Syndrome Coronavirus), first discovered in 2012. Being a relatively novel virus, treatment options are very limited, with no antiviral therapy approved for treating patients yet. Outbreaks of MERS-CoV represent a great challenge since there is very limited time to develop and test new pharmaceutical drugs. Up until now, supportive medical care, along with untested convalescent plasma, have been the only treatment options. However, reuse of drugs for other viruses is presenting as an attractive alternative for MERS-CoV.[1]
Medical Therapy
MERS represents a great challenge in terms of treatment because it is caused by a relatively novel virus to which there is no approved therapy yet. According to the International Severe Acute Respiratory & Emerging Infection Consortium (ISARIC), supportive medical care continues to be the approved treatment for MERS. The search for broad-spectrum inhibitors aiming to minimize the impact of coronaviruses infections remains the major goal. Recent studies are showing the potential use of other drugs and therapies to treat the MERS-CoV, which are based on the experience in treating other coronaviruses like the SARS virus. This repurposing of drugs has advantages such as: better availability, lower cost and known safety and tolerability profiles. However, lack of evidence makes these new therapies uncertain.[1] ISARIC recommends, additionally to routine investigations, that some approaches are more worth of consideration for experiment. These include:[2]
- Convalescent plasma - this therapy, along with others that involve antibodies for the MERS-CoV has the strongest evidence for intervention. Plasma from patients who recovered from MERS-CoV infection contains neutralizing antibodies, which represents the best therapy to neutralize the extracellular virus.
- Intravenous immunoglobulin -
- Interferon -
- HIV Protease Inhibitors -
- Ribavirin -
- Corticosteroids -
- Nitazoxanide -
References
- ↑ 1.0 1.1 Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J; et al. (2014). "Repurposing of clinically developed drugs for treatment of Middle East Respiratory Coronavirus Infection". Antimicrob Agents Chemother. doi:10.1128/AAC.03036-14. PMID 24841273.
- ↑ "Treatment of MERS-CoV: Decision Support Tool".